论文部分内容阅读
目的探讨调脂治疗对2型糖尿病患者早期胰岛素分泌功能的改善作用。方法入组对象为新诊断的2型糖尿病患者118例,血脂正常者40例(T2DM-1组)及血脂异常者30例(T2DM-2组)仅接受单纯降糖治疗;血脂异常者48例(T2DM-3组)应用调脂联合降糖治疗,疗程共3月。治疗前后测血糖、血脂,行口服葡萄糖耐量试验(OGTT),计算OGTT中早期胰岛素分泌功能指数△I30/△G30。结果三组在研究终点时,糖化血红蛋白(HbA1c)均达标;T2DM-3组血脂达理想水平,而且在治疗中期早期胰岛素分泌功能指数△I30/△G30已经得到改善,至终点时与T2DM-1组恢复到相似水平,但T2DM-3组升高幅度明显大于T2DM-1组(P<0.05);T2DM-2组在治疗终点时血脂也得到不同程度的改善,但未达理想水平,终点时早期胰岛素分泌功能指数△I30/△G30与其他两组比较差异有统计学意义(P<0.05)。结论短期的调脂治疗能够改善伴脂代谢紊乱的初发2型糖尿病患者早期胰岛素分泌功能。
Objective To investigate the effect of lipid-lowering treatment on early insulin secretion in type 2 diabetic patients. Methods A total of 118 patients with newly diagnosed type 2 diabetes mellitus (T2DM-1) and 30 patients with dyslipidemia (T2DM-2) were enrolled in this study. (T2DM-3) application of lipid-lowering therapy combined with lipid-lowering therapy, a total of 3 months. Blood glucose and blood lipids were measured before and after treatment. The oral glucose tolerance test (OGTT) was performed to calculate the early insulin secretion function index (△ I30 / △ G30) in OGTT. Results The HbA1c level was reached at the end of the study. The levels of lipids in T2DM-3 group reached the ideal level, and the function index of insulin secretion △ I30 / △ G30 had been improved early in the middle of treatment. When the end point was compared with that of T2DM-1 (P <0.05). The level of blood lipid in T2DM-3 group was also improved to some extent at the end of treatment, but it did not reach the ideal level. At the end point Early insulin secretion function index △ I30 / △ G30 compared with the other two groups was statistically significant (P <0.05). Conclusion Short-term lipid-lowering therapy can improve early insulin secretion in patients with newly diagnosed type 2 diabetes with lipid metabolism disorders.